Offer - Urjas Oil for just ₹ 1
Folitrax 20 Mg Injection is a prescription drug, available for use as Injection. Primarily, it is used for the treatment of Non-Hodgkin Lymphoma, Lymphoma. Secondary and off-label uses of Folitrax 20 Mg Injection have also been mentioned below.
The optimal dosage of Folitrax 20 Mg Injection is largely dependent on the individual's body weight, medical history, gender and age. The condition it has been prescribed for, and the route of administration also determine the right dosage. Detailed information has been provided in the dosage section.
Folitrax 20 Mg Injection also has some side effects, the most common being Abdominal Pain. Some other side effects of Folitrax 20 Mg Injection have been listed ahead. Normally, these side effects of Folitrax 20 Mg Injection are not long lasting and go away when the treatment is finished. If, however, they worsen or do not go away, please speak with your physician.
Furthermore, you should know that effect of Folitrax 20 Mg Injection is Severe for pregnant women and Severe for women who are breastfeeding. Warnings related to Folitrax 20 Mg Injection's effects on the liver, heart and kidney, if any, have been listed below.
Individuals suffering from medical conditions like Infections, Liver Disease, Anemia must refrain from the use of Folitrax 20 Mg Injection since this can cause severe adverse effects. The section on Folitrax 20 Mg Injection contraindications lists all such conditions.
Additionally, Folitrax 20 Mg Injection may also adversely react with other medicines. Refer to the list below for further details.
You should also be aware that Folitrax 20 Mg Injection is safe while driving, and is addiction.
Folitrax 20 Mg Injection is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
Is the use of Folitrax 20 Mg Injection safe for pregnant women?
Folitrax shows severe side effect on pregnant women. For this reason, pregnant women should only take it after taking medical advice.
Is the use of Folitrax 20 Mg Injection safe during breastfeeding?
Folitrax should not be taken without taking your doctor's advice, as it may have severe side effects on breastfeeding women.
What is the effect of Folitrax 20 Mg Injection on the Kidneys?
There may be some adverse effects on kidney after taking Folitrax. If you observe any such side effects, stop taking this drug. Consume this medicine again only if your doctor advises you to do so.
What is the effect of Folitrax 20 Mg Injection on the Liver?
Folitrax may cause harmful effects on liver. if you feel it's having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Folitrax 20 Mg Injection on the Heart?
Side effects of Folitrax rarely affect the heart.
If you are suffering from any of the following diseases, you should not take Folitrax 20 Mg Injection unless your doctor advises you to do so -
Is this Folitrax 20 Mg Injection habit forming or addictive?
Folitrax 20 Mg Injection is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can operate a vehicle or heavy machinery after taking Folitrax 20 Mg Injection since it does not cause drowsiness.
Is it safe?
Folitrax 20 Mg Injection should be used only after doctor's advice.
Is it able to treat mental disorders?
No, Folitrax 20 Mg Injection cannot treat any kind of mental disorder.
Interaction between Food and Folitrax 20 Mg Injection
There is no information on the effects of taking Folitrax 20 Mg Injection with food, because this topic has not been scientifically researched yet.
Interaction between Alcohol and Folitrax 20 Mg Injection
Chances of side effects of drinking alcohol while taking Folitrax 20 Mg Injection are low. If you feel any adverse effects, please seek medical advice as soon as possible.
Folitrax contains methotrexate which is a chemotherapy drug that works in cancer by preventing the DNA synthesis of cancerous cells. It inhibits dihydrofolic acid reductase enzyme which is important for the formation of tetrahydrofolate. Tetrahydrofolate is essential for the synthesis of some DNA components of the cancerous cells. Incase of autoimmune and inflammatory diseases such as psoriasis, rheumatoid arthritis, and Crohn's disease Folitrax works by suppressing the body's normal immune response to inflammation. This results in reduced inflammation and provides relief from the symptoms associated with these diseases.
No, Folitrax is not a steroid. It is an antimetabolite (a chemotherapy drug) and disease-modifying antirheumatic drug (DMARDs) which have immunosuppressant properties. It is used in the treatment of various types of cancer and other diseases such as psoriasis, rheumatoid arthritis, and Crohn's disease.
No, Folitrax does not raise blood sugar levels (hyperglycemia). It has not been reported by the patients who are taking it. However, if you are experiencing increased thirst, trouble concentrating, and frequent urination which are symptoms of increased blood sugar levels (hyperglycemia) then do discuss with your doctor.
Take Folitrax as directed by your doctor. Do not take this medicine longer than prescribed to avoid unpleasant side effects.
Folitrax contains methotrexate (a chemotherapy) which is used in the treatment of various types of cancers. Nonetheless, it has been associated with an increased risk for melanoma, non-Hodgkin's lymphoma, and lung cancer.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Methotrexate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 862-863
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 832-834
